title: [Abnormal expression of chemokine receptor on B cells in patients with SLE].
abstract: SLE is a systemic autoimmune disease characterized by overactivation of autoreactive memory B cells. However, little is known about the mechanism of qualitative abnormality of B cells. The subset classification of T cells by expression pattern of master transcription factors and chemokine receptors has been established. The biology of T cells is useful information to assess qualitative abnormality of B cells. Therefore, we focused on the expression of chemokine receptors such as CXCR5 and CXCR3 on B cells in order to define the B cell subset classification in patients with SLE. Our results revealed that pathological B cells, which lose CXCR5 and express CXCR3, might be involved in autoantibody production through the interaction with Tfh cells, and in acquisition of effector function of memory B cells during the pathological process in SLE. In addition, the results revealed that those effector B cells still remained after improvement of disease activity by immunosuppressive therapy, indicating that the quantitative abnormality, which is not improved by current therapy, may underlie in this disease.
authors.affiliation: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health.
authors.forename: Maiko
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: Shingo
authors.initials: S
authors.lastname: Nakayamada
authors.forename: Shigeru
authors.initials: S
authors.lastname: Iwata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kubo
authors.forename: Naoki
authors.initials: N
authors.lastname: Yunoue
authors.forename: Sheau-Pey
authors.initials: SP
authors.lastname: Wang
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D001323:Autoantibodies / Q000096:biosynthesis; D016175:B-Lymphocyte Subsets / Q000145:classification / Q000276:immunology* / Q000378:metabolism; D002450:Cell Communication; D006801:Humans; D007165:Immunosuppression Therapy; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000628:therapy; D019707:Receptors, Chemokine / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
chemical_list: D001323:Autoantibodies; D019707:Receptors, Chemokine